BENSALEM, Pa.–(BUSINESS WIRE)–Law Offices of Howard G. Smith announces an investigation on behalf of Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) investors concerning the Company and its officers’ possible violations of federal securities laws.
On May 2, 2016, Trevena announced that it had “reached general agreement” with the U.S. Food and Drug Administration concerning key elements of its Phase 3 program for oliceridine (TRV130). Then the FDA released a briefing document in advance of its October 11, 2018 vote on the efficacy and safety of the treatment; in this briefing document the reviewers noted that oliceridine has abuse and overdose potential. On this news, shares of Trevena fell $1.91 or 64%, to close at $1.07 on October 9, 2018, thereby injuring investors.
If you purchased Trevena securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.